Results 211 to 220 of about 198,722 (342)

Metabolic reprogramming-a breakthrough point in overcoming resistance to BRAF mutant melanoma targeted therapy (Review). [PDF]

Oncol Lett
Zhao X, Chen F, Li H.
europepmc   +1 more source

BRAF Negative [PDF]

, 2020
openaire   +1 more source

Painful Bilateral Necrosis of the Scalp

JEADV Clinical Practice, EarlyView.
Zoé Dumesnil, Manuel Croix, Anael Dumont, Kottler Diane, Mohamed‐Taha Tagmouti, Anne Dompmartin, Jean‐Matthieu L'Orphelin   +6 more
wiley   +1 more source

Advances and Future Perspectives for the Management of Non‐Small Cell Lung Cancer in Australia: A Narrative Review

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Lung cancer remains Australia's leading cause of cancer death. With new screening and evolving therapies, equitable access and workforce readiness are essential. This review discusses current and emerging treatments for NSCLC in Australia, clinical trials underway, and future directions in delivering optimal, accessible care nationwide.
Lauren Julia Brown, Graham Meredith, Bo Gao, Pei Ding, Harriet Gee, Inês Pires da Silva, Adnan Nagrial, Eric Hau   +7 more
wiley   +1 more source

Attenuation of the CpG island methylator phenotype and lack of WNT signalling activation restrains Kras mutant intestinal neoplasia. [PDF]

Br J Cancer
Fennell L, Liu C, Kane A, Tria S, Borowsky J, Chai L, Randall-Demllo S, McKeone D, Bond C, Leggett B, Whitehall V.   +10 more
europepmc   +1 more source

BRAF Gene [PDF]

, 2020
openaire   +1 more source

Real‐World Survival Outcomes in EGFR‐Mutant Advanced NSCLC Treated With EGFR TKIs: Insights From a Single‐Center Clinical Data Warehouse Analysis in South Korea

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This retrospective cohort study was conducted using clinical data derived from a single‐center clinical data warehouse (CDW). In Korean patients with EGFR‐mutant advanced NSCLC, first‐line treatment with 3G EGFR TKIs (osimertinib or lazertinib) demonstrated significantly better overall survival than 1G or 2G agents.
Bomi Kim, Sunghoon Kang, Iksoo Huh, Hyeoneui Kim   +3 more
wiley   +1 more source

A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer. [PDF]

Future Oncol
Johnson ML, Smit EF, Felip E, Ramalingam SS, Ahn MJ, Tsao A, Johnson BE, Offin M, Hussein M, Dagogo-Jack I, Goldman JW, Clarke JM, Negrao MV, Sanborn RE, Morgensztern D, Usari T, Wilner K, Alejandro L, Rifi N, Zhang X, Riely GJ.   +20 more
europepmc   +1 more source

Circulating tumour cells (CTCs) in haematological malignancies: Advances in biology and clinical relevance with a focus on multiple myeloma

British Journal of Haematology, EarlyView.
Spatial heterogeneity limits the sensitivity of bone marrow biopsies, resulting in false‐negative findings. Circulating tumour cells (CTCs) provide a systemic, stratified monitoring approach, using flow cytometry for high tumour burden and EuroFlow or allele‐specific oligonucleotide PCR (ASO‐PCR) for minimal residual disease to enable early relapse ...
Chin‐Mu Hsu, Jui‐Feng Hsu, Jee‐Fu Huang, Yi‐Chang Liu   +3 more
wiley   +1 more source

Assessing the clinical diagnostic utility of multiplex ddPCR assays in thyroid nodules. [PDF]

Thyroid Res
Li X, Shen C, Peng X, Xu Q, Zhang J, He M, Kong M, Lin Z, Luo J, Wang Y.   +9 more
europepmc   +1 more source